Boehringer Ingelheim Strengthens Obesity Pipeline as Potential First-in-Class Triple Receptor Agonist BI 3034701 Enters Phase II Development

Phase 2BI 3034701Positive

AI Analysis

Summary

Boehringer Ingelheim announced the initiation of a Phase II clinical trial for BI 3034701, a potential first-in-class triple GLP-1/GIP/NPY2 receptor agonist, in patients with obesity and overweight.

Clinical Trial Data

Phase

Phase II

Importance:6/10

Sentiment:

0.70

obesityGLP-1 receptor agonistGIP receptor agonistNPY2 receptor agonisttriple receptor agonistfirst-in-classclinical development

Related Companies

$TRAX

Read the original article

Published by Drugs.com Clinical Trial Results on July 16, 2026 10:07 PM

Read Original